Regeneron Pharmaceuticals Says Libtayo Achieves 37% Reduction In Risk Of Death At 44 Months (Hr 0.63)
Oct 25 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:
REGENERON PHARMACEUTICALS - LIBTAYO ACHIEVES 37% REDUCTION IN RISK OF DEATH AT 44 MONTHS (HR: 0.63)
REGENERON PHARMACEUTICALS - LIBTAYO CONFIRMS SUSTAINED DISEASE-FREE SURVIVAL BENEFIT INCLUDING MRD NEGATIVE PATIENTS
Further company coverage: REGN.O